Anogenital and oropharyngeal cancers that are attributed to oncogenic strains of the human papillomavirus (HPV) number approximately 31 500 per year in the United States (https://www.cdc.gov/cancer/hpv/ statistics/cases.htm), and despite the availability of a safe and effective HPV vaccine that protects against these strains, the United States has a disappointing record of vaccine uptake after more than a decade of promoting the vaccine for adolescents.To date, national strategies to improve HPV vaccine uptake have centered primarily on health care clinicians (pediatricians, obstetrician-gynecologists, and family practice physicians) and campaigns to encourage and train primary care practitioners on HPV vaccination; the returns on these campaigns have been modest. Data from 2016 showed that 60.4% of adolescents aged 13 to 17 years received at least 1 dose of the vaccine, and only 43.4% of adolescents were up to date with the vaccine. 1 Focusing solely on individual-and interpersonal-level strategies (ie, the medical clinician and the parent) limits the opportunity to reach the level of HPV vaccine coverage that is desired in the United States and that has been achieved by other nations that have developed successful HPV immunization programs, such as Australia, Canada, and the United Kingdom.After more than a decade of promoting a strategy that is not sufficient, additional approaches to improving vaccine uptake should be considered. One of the most obvious tactics would be promoting and implementing state-level school entry requirements for the HPV vaccine along with other adolescent vaccines, such as the tetanus-diphtheria-pertussis vaccine, that already are required for middle school entry in most states. 2 However, discussions related to including HPV vaccine school entry requirements at a policy level are not only rare, but are also often overlooked, such as in the case of the 2014 report of the President's Cancer Panel. 3 The panel described the low vaccine rates and recommended 3 goals for increasing rates in the United States that focused on clinician-based vaccination strategies, such as developing communication programs that are associated with the HPV vaccine for physicians. There is a brief mention of school-based and school-located programs, which have been successful in other countries, but the panel concluded that there are too many barriers to implementing those programs in the United States. However, there was a caveat that stated "Furthermore, if vaccination rates in the United States do not improve dramatically over the next several years, the feasibility of school-located vaccination should be reexamined." 3